Stem Cell Trial Wins Approval of F.D.A.
US Pharma Fury Over New Moves to Ban Pay-For-Delay Deals
Sanofi May Make Hostile Bid if Genzyme Resists, Citigroup Says
Allergan Beats Street as Botox, Devices on Rebound
Adult Stem Cell Research Far Ahead of Embryonic
Sigma Attracts New Bidder for Generic Drugs Business, Morning Herald Says
SUBSCRIBE